HOME >> BIOLOGY >> NEWS
Hemocellular Therapeutics establishes licensing agreement with UNC, ECU

CHAPEL HILL -- Hemocellular Therapeutics, expected to produce the first platelet-based therapeutic available to doctors for the immediate treatment of active bleeding, has established an exclusive licensing agreement with the University of North Carolina at Chapel Hill and East Carolina University, company officials recently announced.

The agreement recognizes key technology developed by researchers at the two universities as central to the N.C. company's planned creation of lyophilized, or "freeze-dried," human platelets the component of blood primarily responsible for initiation of coagulation. As a part of the exclusive license agreement, both universities received equity in Hemocellular and will share in royalties on the eventual sale of products.

Hemocellular's freeze-dried platelets are the result of a decade of research supported by initial federal research funding of $10 million.

The company's scientific founders, Dr. Arthur P. Bode of ECU and Dr. Thomas H. Fischer of UNC, have led the research efforts. Bode, who received his doctorate in experimental pathology from UNC, has served as ECU's scientific director of clinical coagulation programs for 15 years.

Fischer is scientific director of UNC's Francis Owen Research Laboratory, where researchers discovered the molecular cell membrane cross-linking technology crucial to Hemocellular's product development, said Richard A. Basile, chief executive officer of the company, and the initial extensive series of trials have taken place at that lab.

"The Francis Owen lab has a worldwide reputation in the field of coagulation therapeutics. We are extremely fortunate to have researchers affiliated with this lab informing our efforts to bring this technology to health-care settings as rapidly and responsibly as possible," he said.

Basile added that the licensing agreement is key in advancing platelet development to the next stage: human clinical trials. No other func
'"/>

Contact: Deb Saine
919-962-8415
University of North Carolina at Chapel Hill
15-May-2003


Page: 1 2 3

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
4. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
5. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
6. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
7. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
8. Immerge BioTherapeutics announces identification of PERV receptor
9. Acorda Therapeutics acquires CeNeS neuregulin products
10. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
11. Genome Therapeutics, University of Southampton and Schering-Plough identify novel asthma gene

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in ... 3 VISTA-2 study of SkQ1 ophthalmic solution in patients with moderate to ...
(Date:8/23/2020)... , ... August 21, 2020 , ... ... Corporation has been published and is now available on the company’s global ... diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. , ...
(Date:8/21/2020)... ... August 19, 2020 , ... ... conference and expo uniting life science, data science, informatics and IT leaders goes ... “In this period of uncertainty and change, Bio-IT takes the leadership role of ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... ... 29, 2020 , ... DuPont Nutrition & Biosciences announced today ... new plant operation will provide the local animal production industry with customized solutions ... will improve the flexibility of our offerings to the Chinese animal nutrition market,” ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... engineering firm, is making available for free its new white paper – ... transport simulation testing into today’s biologics licensing application (BLA). In response, Modality ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics ... , Known as MediVet Biologics since its formation in 2016, the company ... Ardent Animal Health will build on its base of innovative therapies for osteoarthritis and ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... can combine up to three different materials for use with CRM, neurostimulation, vascular, ... to three materials to meet specific design requirements, performance, and cost criteria; especially ...
Breaking Biology Technology:
Cached News: